Global NewsHigh Priority (9/10)Usa

FDA Approves Eli Lilly's Foundayo as Second Oral GLP-1 Obesity Treatment

The FDA has approved Foundayo, a new oral obesity medication from Eli Lilly, making it the second GLP-1 therapy available as a pill after Wegovy, offering patients a convenient alternative to injectable treatments.

Key Points

  • FDA approved Foundayo, developed by Eli Lilly, for obesity treatment
  • Foundayo is only the second GLP-1 therapy approved as an oral pill (after Wegovy)
  • Provides convenient oral alternative to injectable GLP-1 treatments
  • Represents major milestone in expanding obesity treatment options

Full Details

The FDA has approved Foundayo, developed by pharmaceutical company Eli Lilly, as a new oral medication for obesity treatment. This approval marks a significant milestone in obesity care as Foundayo becomes only the second GLP-1 (glucagon-like peptide-1) therapy approved in pill form, following Wegovy. The oral formulation offers a convenient alternative to the standard injectable GLP-1 therapies that have proven effective for weight loss but require needles. This development represents a major shift in obesity treatment options, potentially increasing accessibility for patients who prefer oral medications over injections. The approval expands treatment choices for the millions of Americans struggling with obesity.

Why It Matters

The approval of oral GLP-1 medications could significantly expand access to effective obesity treatments, as many patients avoid injectable therapies. This may intensify competition in the weight loss medication market and potentially lower costs over time.

Sourceforbes.com

Get stories like this delivered daily

AI-curated news, personalized to your interests. Zero noise.

Start 7-Day Free Trial →

More in Global News